The Diagnostics & Lab Testing Business Brief cover art

The Diagnostics & Lab Testing Business Brief

The Diagnostics & Lab Testing Business Brief

By: Damon Frank
Listen for free

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary
The Diagnostics & Lab Testing Business Brief delivers a daily briefing on the business, technology, innovation, and market forces shaping the global diagnostics industry. From diagnostic devices, medical technology, AI-powered diagnostics, laboratory testing, and continuous glucose monitors (CGMs) to emerging testing technologies, point-of-care diagnostics, molecular diagnostics, and at-home testing, we cover the innovations transforming how diseases are detected, monitored, and diagnosed. Stay informed on earnings, mergers and acquisitions, venture funding, FDA approvals and clearances, regulatory developments, product launches, clinical breakthroughs, and competitive shifts across the diagnostics marketplace. Follow industry leaders including Labcorp, Quest Diagnostics, Abbott, Roche, Siemens Healthineers, Danaher, and Thermo Fisher Scientific, alongside the startups and innovators reshaping the future of diagnostics. Created for diagnostics executives, medical technology leaders, laboratory operators, founders, investors, entrepreneurs, and industry professionals who need to understand what's happening, why it matters, and where the industry is heading. Presented by Damon Frank, marketing strategist, media entrepreneur, and founder of Talent Branded. Produced using AI-assisted research and narration.@ Talent Branded Entertainment, Inc. Economics Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • The Diagnostics & Lab Testing Business Brief — Monday, November 16, 2026
    Nov 16 2026

    The Diagnostics & Lab Testing Business Brief — Monday, November 16, 2026

    • Roche Diagnostics makes its Endotrophin (ETP) research prototype assay available on cobas e801 analyzers at Nordic Bioscience's CLIA laboratory — the second biomarker from the Roche–Nordic collaboration to reach the platform, following the CE-marked Elecsys PRO-C3. (PR Newswire)
    • Alamar Biosciences' NULISA precision proteomics platform features in 46 presentations at CTAD 2026 in Boston, including data showing brain-derived p-tau217 had the strongest association with amyloid and tau accumulation and cognitive progression among 328 plasma proteins in the A4 and LEARN studies. (GlobeNewswire)
    • Arkansas Children's Hospital laboratory develops and validates a molecular measles assay that distinguishes disease-causing from vaccine strains of the virus, presented at the AMP annual meeting in Seattle. (GenomeWeb)
    • Biovica receives a second work order, valued at approximately $150,000, under its expanded master services agreement with a leading global pharmaceutical company for DiviTum TKa testing in an oncology program, to be run at its CLIA-certified San Diego laboratory. (ACCESS Newswire)
    Show More Show Less
    8 mins
  • The Diagnostics & Lab Testing Business Brief — Sunday, November 15, 2026
    Nov 15 2026

    The Diagnostics & Lab Testing Business Brief — Sunday, November 15, 2026

    • VedaBio presents proof-of-concept data at AMP 2026 showing under-10-minute sample-to-answer molecular detection with its target amplification-free CRISPR technology, using a five-result respiratory panel prototype with automated nucleic acid extraction. (Business Wire)
    • NeuroKaire showcases its BrightKaire platform at HLTH 2026: from a standard blood draw, patient-specific functional neurons are generated and antidepressants ranked, with company-reported AUC of 0.81 and 84% positive predictive value. (GlobeNewswire)
    • Feminai, developer of a wearable sensor patch using AI to monitor breast tissue changes for at-home breast cancer screening, captured the $350,000 MedTech Innovator Early-Stage Grand Prize, as ASPS announced its Plastic Surgery Track startups won a combined $355,000. (GlobeNewswire)
    Show More Show Less
    7 mins
  • The Diagnostics & Lab Testing Business Brief — Saturday, November 14, 2026
    Nov 14 2026

    The Diagnostics & Lab Testing Business Brief — Saturday, November 14, 2026

    • Molecular Designs earns its first FDA 510(k) clearance (K262789) for the SimplicityDx Panel FluA/FluB/RSV, a multiplex RT-PCR test for anterior nasal swabs for use in CLIA high-complexity laboratories, with a breakaway format designed to reduce waste. (PR Newswire)
    • Cerenome reports its first quarter of CNSide diagnostic revenue: $0.7 million net on about $1.55 million in gross billings, contracted coverage representing about 190 million covered lives, and an Aetna agreement effective November 1 covering both tumor cell enumeration and molecular profiling. (GlobeNewswire)
    • Owlet Q3 2026: revenue of $30.4 million, subscription revenue of $3.6 million with more than 142,000 Owlet360 paying subscribers, and net income of $1.4 million; the company initiated a camera cable guard safety update and withdrew its full-year 2026 outlook. (Business Wire)
    • A JAMA study led by WashU Medicine finds the blood tau fragment eMTBR-tau243 elevated in advanced chronic traumatic encephalopathy as well as Alzheimer's disease; the measurement technology is licensed to C2N Diagnostics, and the marker has not been validated for diagnosing CTE. (WashU Medicine)
    • VolitionRx Q3 2026: revenue of about $1.6 million, up 157% year over year, operating loss narrowed to $3.3 million, and its French reimbursement submission for the Nu.Q lung cancer test expected this quarter. (PR Newswire)
    Show More Show Less
    7 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.